

Subject: Medical Science Liaison (MSL) Notes - Introduction of PediatricEase

Date: August 15, 2025

Provider: Dr. Lisa Reynolds

Title: Pediatrician

Institution: KidsWell Pediatrics

Summary of Key Discussion Points:

1. Introduction:

- Introduced PediatricEase as an innovative therapy for the management of pediatric migraine in children under 12.
- Emphasized its unique formulation and targeted approach for improved safety in the pediatric population.

2. Provider's Current Patient Cases:

- Dr. Reynolds expressed interest in effective and safe treatments for pediatric migraines.
- Discussed specific cases where current treatments for migraines in children have limitations or adverse effects.

3. Efficacy and Clinical Data:

- Presented recent clinical data showcasing PediatricEase's ability to reduce migraine frequency by 50% and improve overall well-being in pediatric patients.
- Highlighted statistically significant improvements in headache intensity and duration.

4. Safety Profile:

- Discussed the favorable safety profile of PediatricEase, specifically designed to address the unique needs and concerns of pediatric patients.
- Dr. Reynolds inquired about potential interactions with commonly prescribed medications for children.

5. Mechanism of Action:

- Explained PediatricEase's mechanism, focusing on its targeted modulation of specific neurotransmitter pathways involved in pediatric migraines.
- Dr. Reynolds appreciated the detailed explanation and sought insights into its potential for long-term use in children.

6. Patient Adherence and Education:

- Discussed strategies for enhancing patient adherence through a once-daily oral solution with a child-friendly flavor.
- Shared educational materials designed for both parents and children to ensure proper administration and understanding of the treatment.

7. Emerging Research and Future Developments:

- Highlighted ongoing research on PediatricEase's potential in other pediatric headache disorders.
- Discussed plans for exploring combination therapies to address various aspects of pediatric migraines.

8. Competitive Landscape:

- Compared PediatricEase to existing treatments for pediatric migraines, emphasizing its improved safety profile and targeted mechanism.
- Discussed the need for tailored treatment plans considering the specific needs of children.

9. Access and Reimbursement:

- Provided updates on access and reimbursement programs for pediatric clinics.
- Discussed potential affordability concerns and patient assistance programs for families.

10. Action Items and Follow-Up:

- Dr. Reynolds expressed interest in incorporating PediatricEase into her practice for pediatric migraine management.
- Agreed upon a follow-up in three months to assess patient response and discuss any emerging concerns.

11. Closing Remarks:

- Expressed gratitude for Dr. Reynolds's commitment to pediatric care.
- Reiterated commitment to ongoing collaboration and support for KidsWell Pediatrics.